A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes

Summary

The study drug LY2409021 is being evaluated as a possible treatment for diabetes. The primary purpose of this study is to help answer the following research questions, and not to provide treatment for diabetes : * The safety of LY2409021 and any side effects that might be associated with it following 4 weeks of doses * How long it takes the body to absorb and remove LY2409021 following dosing over 4 weeks * How daily dosing of LY2409021 affects blood levels of sugar (glucose), insulin and other naturally occurring substances before and after a meal * How LY2409021 works when given with metformin * How daily dosing of LY2409021 affects the cells that produce insulin

Timeline

Start

2008-03

Primary completion

2008-11

Completion

2008-11

Publications

• Tan AYF, Schneck K, Garhyan P, Chan ECY, Tham LS. Evaluation of Four Semi-Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 Diabetes. CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1381-1390. doi: 10.1002/psp4.70058. Epub 2025 Jun 17.
• Kelly RP, Garhyan P, Raddad E, Fu H, Lim CN, Prince MJ, Pinaire JA, Loh MT, Deeg MA. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22. doi: 10.1111/dom.12446. Epub 2015 Mar 2.

Drugs

Indications